An interventional study of Quality life questionnaire AQoLS and Quality life questionnaire Euroqol EQ-5D-5L in Alcohol Use Disorder, sponsored by Hospices Civils de Lyon. Recruiting at 5 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-21.
Sponsored by Hospices Civils de Lyon · Not applicable, Interventional, and Health services research
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 94 studies in Alcoholism with a site in France — 24 open to participants now, 25 under way, 1 of them phase 3. Alcoholism · France.
Among the 94 studies in Alcoholism with a site in France, this one is the 4th largest by planned enrollment of the 58 interventional ones that give a count, is one of 8 that started in 2026, is one of 42 with no phase, reaches primary completion later than 22 of the 24 other live ones, and was the 79th registered.
1,679 studies on the registry are indexed under Alcoholism; 333 are open to participants now.
Browse Alcoholism studies →24 of the 94 studies in Alcoholism with a site in France are open now. Recruiting first, the newest first:
Institut National de la Santé Et de la Recherche Médicale, France · Sites in France
Ages 18–65
Centre Hospitalier Universitaire de Nīmes · Sites in France
Ages 18+
CHU de Reims · Sites in France
Ages 18–65 · Healthy volunteers
Centre Hospitalier Régional d'Orléans · Sites in France
Ages 18+ · Healthy volunteers
CHU de Reims · Sites in France
Ages 24+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 238 Alcoholism studies recruiting now, 85 (36%) set no upper age limit and 131 (55%) stop at 75 or younger; 9 take children under 18; 64 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
94 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 6 · Phase 3 8 · Phase 4 2
First in 2002; this study’s year is marked. 8 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 626 is above the median of 88 across 1,433 interventional studies indexed under Alcoholism.
Median enrollment 153 across the 58 interventional studies, 113 across the 36 observational. Of the 59 that completed or were terminated, 1 (2%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 94 have an industry lead sponsor. The 10 most frequent:
Hospices Civils de Lyon is the lead sponsor of 1,868 studies on the registry; 447 are open to participants now.
Hospices Civils de Lyon has 1 study filed under Alcoholism — fewer than ten, so there is no comparison to draw.
5 of the studies in Alcoholism with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07369245Versailles HospitalTechniques for Activating Consciousness (TAC) for Outpatients With Moderate to Severe Alcohol Addiction | 2027-07-15 |
| NCT04773691Centre Hospitalier Universitaire DijonEffectiveness of High-frequency rTMS in Reducing Alcohol Consumption in Non-abstinent Patients With an Alcohol Use Disorder | 2027-08 |
| NCT06706349Centre Hospitalier Universitaire de BesanconEffect of Adapted Physical Activity on Sleep Quality in People With Alcohol Use Disorder | 2027-10 |
| NCT06675539Etablissement Public de Santé Barthélemy DurandValidation of the French Version of the Prediction of the Alcohol Withdrawal Severity Scale (PAWSS) | 2027-10 |
| NCT07844720Institut National de la Santé Et de la Recherche Médicale, FranceStudy on Thiamine Supplementation to REduce braiN Injury Associated With Chronic Alcohol Use in Outpatients With Alcohol Use Disorder | 2027-10-22 |
Add all 5 to your calendar (.ics) → With an account.
Among the 94 studies in Alcoholism with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Alcohol use disorder (AUD) affects between 4% and 6% of French adults, and requires appropriate medical treatment.
However, 20-40% of patients with AUD are lost to follow-up at an early stage. Consequently, it is important for addiction departments to implement and evaluate innovative tools and interventions, including the involvement of peer support, to help patients remain in care, and to assess whether peer support has a positive impact on their clinical outcome.
Addiction peer support specialists (APSSs) are individuals who have personally experienced addiction, and who have decided to use their experience to assist other people going through a similar situation, after completing a specific official graduation.
Compared to other caregivers, APSSs may induce in patients a sense of identification which could improve the patient motivation to engage and remain in care.
This is the main hypothesis and the main scientific objective of the PEERSIAD study, which will aim to confirm that accompanying patients with AUD using APSSs after alcohol detoxification, reduces the rate of lost-to-follow-up and improves the overall clinical outcome.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
313 patients will be recruited over 3 years in the peer support group. Patients will be accompanied by an addiction peer support specialist, as part of an "add-on" follow-up compared with conventional follow-up (same management as in the control group).
Behavioral: Quality life questionnaire AQoLS · Behavioral: Quality life questionnaire Euroqol EQ-5D-5L · Other: Peer support consultations
313 patients will be recruited over 3 years in the control group. Patients will receive "as usual" outpatient abstinence-maintenance follow-up, with consultations of all kinds (medical, psychological, nursing, group, etc.)
Behavioral: Quality life questionnaire AQoLS · Behavioral: Quality life questionnaire Euroqol EQ-5D-5L
Quality life questionnaire AQoLS will be completed by patients of both arms at inclusion, three and six months after inclusion
Quality life questionnaire Euroqol EQ-5D-5L will be completed by patients of both arms at inclusion, three and six months after inclusion
For patients included in the Peer support group, eight mandatory consultations with a peer support specialist will be performed between the inclusion visit and during the three following months. Patients can request additional consultations with the peer support specialist during the 6 first months of follow-up
Unplanned cessation of care at 6 months
The unplanned cessation of care at 6 months, excluding consultations with an APSS, with no further contact in the following month, is defined as having had a last planned consultation that was not fulfilled between M0 and M6
Time frame: At 6 months after inclusion
Number of unfulfilled consultations
The number of unfulfilled consultations (scheduled consultations, excluding Peer Support consultations, without patient's visit with or without justification) over the 6-month study follow-up period, collected from the medical records of the addictology department.
Time frame: 6 months after inclusion
Euroqol-5D-5L questionnaire score
The differential cost-utility ratio, in relation to the innovative strategy including a Peer Support, will be assessed using the Euroqol-5D-5L questionnaire (EQ-5D-5L).
Time frame: At inclusion, 3 and 6 months after inclusion
Difference in costs (in euros)
An additional analysis will be carried out if the cost-utility ratio is positive: Difference in costs (in euros) for the payer (French compulsory health insurance) between a scenario in which the innovative management is implemented and disseminated in practice and on French territory, and a scenario in which usual follow-up is maintained.
Time frame: At 1, 2 and 3 years after the beginning of implementation on French territory
Number of AUD criteria according to Diagnostic and Statistical Manual of Mental Disorders (DSM-5)
Time frame: At inclusion, 3 and 6 months after inclusion
Alcohol Use Disorders Identification Test-Consumption (AUDIT-C) score
Time frame: At inclusion, 3 and 6 months after inclusion
average number of standard drinks declared per week
Time frame: At inclusion, 3 and 6 months after inclusion
Alcohol Quality of Life Scale (AQoLS) score
Changes in quality of life will be measured using the AQoLS
Time frame: At inclusion, 3 and 6 months after inclusion
State-Trait Anxiety Inventory (STAI-Y) score
Changes in levels of anxiety will be measured using STAI-Y
Time frame: At inclusion, 3 and 6 months after inclusion
Montgomery-Åsberg Depression Rating Scale (MADRS) score
Changes in levels of depression will be measured using MADRS
Time frame: At inclusion, 3 and 6 months after inclusion
Cannabis Use Disorders Identification Test - Revised (CUDIT-R) score
Changes in the severity of cannabis use will be measured by the CUDIT-R score
Time frame: At inclusion, 3 and 6 months after inclusion
type of opioid use
Time frame: At inclusion, 3 and 6 months after inclusion
frequency of opioid use
Time frame: At inclusion, 3 and 6 months after inclusion
type of psychostimulant use
Time frame: At inclusion, 3 and 6 months after inclusion
frequency of psychostimulant use
Time frame: At inclusion, 3 and 6 months after inclusion
Fagerström test score
Tobacco use will be measured by the Fagerström test
Time frame: At inclusion, 3 and 6 months after inclusion
Health Care Satisfaction Questionnaire (HCSQ) score
Patient's satisfaction will be measured by HCSQ questionnaire
Time frame: At 6 months after inclusion
Number of hospitalisations
Measurement of the number of hospitalisations related or not to the AUD and the ratio of total hospital days to number of hospital admissions (based on medical records and patient interviews)
Time frame: At 6 months after inclusion
Service organization description
Time frame: Before setting up of the study
Description of type of support and missions performed by Peer Support
Time frame: After last visit of last patient (around 3,5 years after first inclusion)
Acceptability of Intervention Measure (AIM) score
AIM score measured in Peer Support and medical staff
Time frame: After last visit of last patient (around 3,5 years after first inclusion)
AIM score
AIM score measured in patients
Time frame: At 6 months after inclusion
Adoption of intervention
adoption of intervention will be assessed through semi-structured interviews and measurement of the number of patients followed-up versus the number of eligible patients, refusals to be accompanied by APSS, and premature discontinuation of follow-up
Time frame: After last visit of last patient (around 3,5 years after first inclusion)
Intervention fidelity
intervention fidelity will be assessed by monitoring APSS activity indicators, describing deviations from the protocol and semi-structured interviews
Time frame: After last visit of last patient (around 3,5 years after first inclusion)
Plan to share: No
No publications or documents are linked to this record.
Started Oct 2026 (actual). Primary completion is estimated for Apr 2030, 42 months after the start.
Of 472 non-industry interventional studies with no phase under Alcoholism, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 54. This study's planned 42 months is above that.
Counting every sponsor, half of 495 studies reached it within 33 months; a quarter within 17 and three quarters within 52.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 21, 2026: start Oct 2024 → Oct 2026, primary completion Apr 2028 → Apr 2030 and completion Apr 2028 → Apr 2030.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.